Form 4: Eli Lilly Director Ralph Alvarez Defers Compensation into Company Stock

Eli Lilly & Co. Director Ralph Alvarez acquired 15.416 shares of common stock through a compensation deferral plan, aligning his interests with shareholders.

Summary

• Director Ralph Alvarez acquired 15.416 shares of Eli Lilly & Co. common stock.
• The transaction occurred on July 21, 2025, at a price of $762.18 per share.
• The shares were acquired as part of a deferral of cash compensation under the Lilly Directors' Deferral Plan.
• These shares will be settled in common stock following Mr. Alvarez's separation from service.
• Following this transaction, Mr. Alvarez beneficially owns 54,994.58 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a small transaction, it represents a director's continued alignment with shareholder interests through equity ownership, which is generally viewed favorably.

Positives

• The acquisition of shares by a director aligns management's interests with those of shareholders, demonstrating confidence in the company's future performance.
• The deferral of cash compensation into stock units under a formal plan indicates a structured approach to executive remuneration and long-term commitment.

Future Outlook

The filing indicates that the acquired stock units will be settled in shares of common stock following the reporting person's separation from service, implying a long-term holding period for these specific shares.

Industry Context

This transaction is a routine insider filing related to director compensation within the pharmaceutical industry, reflecting standard corporate governance practices for aligning director incentives with company performance.

Comparison to Industry Standards

• The practice of deferring cash compensation into company stock is a common corporate governance mechanism across various industries, including pharmaceuticals, to align the interests of directors and executives with long-term shareholder value.
• Many large pharmaceutical companies, similar to Eli Lilly, utilize director deferral plans to encourage long-term equity ownership among their board members, such as Pfizer, Johnson & Johnson, and Merck & Co.

Corporate Governance

Related Party Transactions

• The acquisition of shares by Director Ralph Alvarez from Eli Lilly & Co. as part of his compensation is a related party transaction, structured under the Lilly Directors' Deferral Plan.

Stakeholder Impact

• Shareholders: The transaction reinforces alignment between the director's interests and shareholder value, potentially fostering greater confidence.
• Director: The director receives compensation in the form of company equity, linking personal wealth to company performance.

Next Steps

• The acquired stock units will be settled in shares of common stock following the reporting person's separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Ralph Alvarez, Director Compensation, Stock Acquisition, SEC Form 4, Insider Transaction, Deferred Compensation, Pharmaceuticals